Antimicrobial Therapy for Bronchiectasis

Clinics in Chest Medicine

Volumn 33, Issue 2, 2012, Pages 381-386

  O'Donnell, Anne E ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

Antibiotics; Antimicrobial therapy; Bronchiectasis; Maintenance

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; ERYTHROMYCIN; GENTAMICIN; MACROLIDE; QUINOLONE; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; BRONCHIECTASIS; COMBINATION CHEMOTHERAPY; COUGHING; DISEASE EXACERBATION; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; HUMAN; LONG TERM CARE; MAINTENANCE CHEMOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; REVIEW; WHEEZING;

ANTI-BACTERIAL AGENTS; BRONCHIECTASIS; HUMANS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84861560061     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2012.03.005     Document Type: Review

References (40)

1. Morrissey B.M. Pathogenesis of bronchiectasis. Clin Chest Med 2007, 28:289-296.
2. Cole P.J. Inflammation: a two-edged sword: the model of bronchiectasis. Eur J Respir Dis Suppl 1986, 147:6-15.
3. Martinez-Garcia M.A., Soler-Cataluna J.J., Perpina-Tordera M., et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007, 132:1565-1572.
4. King P.T., Holdsworth S.R., Freezer N.J., et al. Microbiologic follow up study in adult bronchiectasis. Respir Med 2007, 101:1633-1638.
5. Nicotra M.B., Rivera M., Dale A.M., et al. Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. Chest 1995, 108:955-961.
6. Pasteur M.C., Helliwell S.M., Houghton S.J., et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000, 162:1277-1284.
7. Li A.M., Sonnappa S., Lex C., et al. Non-CF bronchiectasis: does knowing the aetiology lead to changes in management?. Eur Respir J 2005, 26:8-14.
8. Murray M.P., Pentland J.L., Turnbull K., et al. Sputum colour: a useful clinical tool in non-cystic fibrosis bronchiectasis. Eur Respir J 2009, 34:361-364.
9. Gillham M.I., Sundaram S., Laughton C.R., et al. Variable antibiotic susceptibility in populations of Pseudomonas aeruginosa infecting patients with bronchiectasis. J Antimicrob Chemother 2009, 63:728-732.
10. Griffith D.E. Nontuberculous mycobacterial lung disease. Curr Opin Infect Dis 2010, 23:185-190.
11. Tsang K.W., Bilton D. Clinical challenges in managing bronchiectasis. Respirology 2009, 14:637-650.
12. Pasteur M.C., Bilton D., Hill A.T., et al. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010, 65:i1-i158.
13. Metersky M.L. New treatment options for bronchiectasis. Ther Adv Respir Dis 2010, 4:93-99.
14. O'Donnell A.E. Bronchiectasis. Chest 2008, 134:815-823.
15. Tsang K.W., Chan W.M., Ho P.L., et al. A comparative study on the efficacy of levofloxacin and ceftazidime in acute exacerbations of bronchiectasis. Eur Respir J 1999, 14:1206-1209.
16. Darley E.S., Bowker K.E., Lovering A.M., et al. Use of meropenem 3 g once daily for outpatient treatment of infective exacerbations of bronchiectasis. J Antimicrob Chemother 2000, 45:247-250.
17. Bilton D., Henig N., Morrissey B., et al. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006, 130:1503-1510.
18. Chang K.C., Leung C.C., Yew W.W., et al. Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis?. Eur Respir J 2010, 35:606-613.
19. Biewend M.L., Waller E.A., Aduen J.F., et al. Radiographic evolution and antimicrobial resistance patterns in patients with bronchiectasis treated with cyclic antibiotics. Proc Am Thorac Soc 2005, 2:A176. [abstract].
20. Rayner C.F., Tillotson G., Cole P.J., et al. Efficacy and safety of long-term ciprofloxacin in the management of severe bronchiectasis. J Antimicrob Chemother 1994, 34:149-156.
21. Orriols R., Roig J., Ferrer J., et al. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respir Med 1999, 93:476-480.
22. Barker A.F., Couch L., Fiel S.B., et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000, 162:481-485.
23. Scheinberg P., Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 2005, 127:1420-1426.
24. Murray M.P., Govan J.R., Doherty C.F., et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011, 183:491-499.
25. Dhar R., Anwar G.A., Bourke S.C., et al. Efficacy of nebulized colomycin in patients with non-cystic fibrosis bronchiectasis colonized with Pseudomonas aeruginosa. Thorax 2010, 65:553.
26. Steinfort D.P., Steinfort C. Effect of long-term nebulized colistin on lung function and quality of life in patients with chronic bronchial sepsis. Intern Med J 2007, 37:495-498.
27. White L., Mirrani G., Grover M., et al. Outcomes of pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis. Respir Med 2012, 106:356-360.
28. Cai Y., Chai D., Wang R., et al. Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review. J Antimicrob Chemother 2011, 66:968-978.
29. Alberts R.K., Connett J., Bailey W.C., et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011, 365:689-698.
30. Anwar G.A., Bourke S.C., Afolabi G., et al. Effects of long-term low dose azithromycin in patients with non-CF bronchiectasis. Respir Med 2008, 102:1494-1496.
31. Serisier D.J., Martin M.L. Long-term low dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respir Med 2011, 105:946-949.
32. Cymbala A.A., Edmonds L.C., Bauer M.A., et al. The disease modifying effects of twice-weekly azithromycin in patients with bronchiectasis. Treat Respir Med 2005, 4:117-122.
33. Griffith D.E., Aksamit T., Brown-Elliott B.A., et al. An official ATS/IDSA statement: diagnosis, treatment and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007, 175:367-416.
34. Wilson R., Welte T., Polverino E., et al. Randomized, placebo-controlled, double-blind, multi-center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo in non-cystic fibrosis bronchiectasis. Eur Respir J 2011, 38(Suppl 55):334S. [abstract].
35. Newhouse M.T., Hirst P.H., Duddu S.P., et al. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest 2003, 124:360-366.
36. Bilton D., DeSoyza A., Hayward C., et al. Effect of a 28-day course of two different doses of once a day liposomal ciprofloxacin for inhalation on sputum Pseudomonas aeruginosa density in non-CF bronchiectasis. Am J Respir Crit Care Med 2010, 181:A3191. [abstract].
37. O'Donnell A.E., Swarnakar R., Yashina L., et al. A placebo-controlled study of liposomal amikacin for inhalation once daily in the treatment of bronchiectasis patients with chronic Pseudomonas aeruginosa lung infection. Eur Respir J 2009, 34:23S. [abstract].
38. Geller D.E., Flume P.A., Staab D., et al. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011, 183:1510-1516.
39. Barker A., O'Donnell A., Daley C., et al. Microbiological results of a phase 2 open-label study of aztreonam for inhalation in patients with bronchiectasis and gram-negative bacteria in the airways. Chest 2010, 138:512A. [abstract].
40. MacLeod D.L., Barker L.M., Sutherland J.L., et al. Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J Antimicrob Chemother 2009, 64:829-836.